Molecular Partners (MOLN) Set to Post Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) is anticipated to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.46) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 3:00 AM ET.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings results on Monday, August 24th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01. On average, analysts expect Molecular Partners to post ($1.28) EPS for the current fiscal year and ($0.36) EPS for the next fiscal year.

Molecular Partners Stock Up 2.2%

NASDAQ MOLN opened at $3.75 on Tuesday. The firm’s 50 day moving average is $4.08 and its 200-day moving average is $4.19. The company has a market capitalization of $151.43 million, a PE ratio of -2.19 and a beta of 1.11. Molecular Partners has a 12-month low of $3.52 and a 12-month high of $5.36.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MOLN shares. HC Wainwright reaffirmed a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.